Navigation Links
Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
Date:3/11/2008

BRISBANE, Australia, March 11 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced the commencement of its global phase 3 study investigating PI-88 as an adjuvant treatment for primary liver cancer (hepatocellular carcinoma, HCC) following curative resection with the first patient having been randomized onto the study. The study is known globally as PATHWAY (PI-88 in the adjuvant treatment of HCC). The first patient to enter the trial is from Singapore.

Dr. Ronnie Poon, Ph.D., M.D., global lead investigator for PATHWAY, commented, "My colleagues and I are encouraged by the phase 2 data that Progen has generated for PI-88 in this challenging disease, for which there are no approved treatment options. If PATHWAY is successful, PI-88 could change the standard of care for resected liver cancer patients."

PATHWAY, a double-blinded, placebo-controlled study, has been designed to establish the efficacy and safety of PI-88 in the post resection liver cancer setting. The trial will recruit approximately 600 patients at about 65-70 hospitals in more than a dozen countries. Disease-free survival, a measure of the average length of time that patients remain free of tumor recurrence, is the primary endpoint. Upon completion of this trial, the results are expected to form the basis of global registration filings for PI-88.

Justus Homburg, Progen's CEO, said, "Commencement of this trial represents a significant milestone for Progen. We have designed this trial in collaboration with world experts in this field of medicine, and with USA FDA Fast Track and EU EMEA Orphan Drug Status, its initiation underscores our commitment to making this important drug rapidly available to patients who currently have few treatment options available."

Liver cancer is one of the top five causes of cancer deaths in the world, with over half a million new cases per year. Although surgical resection is one of the few treatme
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
2. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
3. Progen Announces PI-88 Phase 2 Lung Cancer Results
4. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. Inclinix Announces New Patent for Expert System Platform
7. Genzyme Announces Presentation of New Positive Data on Carticel(R)
8. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
9. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
10. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
11. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)... SAN DIEGO, Oct. 7 /- Prometheus Lab..., today announced findings from its,development of...blood test,for irritable bowel syndrome (IBS). The...pression of particular biomarkers in blood samples...ion of these biomarkers,combined with a proprieta...
(Date:10/7/2008)... Results of FLEXX Trial Presented at the Osteoart... Congress, PARSIPPANY, N.J., Oct. 7 /PRNewswire/ ... results from the FLEXX Trial of Osteoarthritis of...luronate), a highly pure,non-avian high molecular ...-HA), is superior to intra-articular saline (IA-sa...
(Date:10/7/2008)... In a clinical study of adults, VYVANSE taken onc...D within one week, PHILADELPHIA, Oct. 7 /PRNewswi...Y), the global specialty biopharmaceutical company...ptember issue of the Journal of,Clinical Psychiatr...Attention Deficit Hyperactivity Disorder (ADHD) sy...
(Date:10/7/2008)... BERKELEY, Calif., Oct. 7 /- Aerovan...fety data from a Phase I trial of its Aerovant,inh...with no evidence of,local irritancy following asth...This 10 mg dose will be the highest of three doses...g study, which is scheduled to begin early,next ye...
Breaking Medicine Technology:Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients 2EuroDYNA takes lid off the genome 3629 1EuroDYNA takes lid off the genome 3629 2EuroDYNA takes lid off the genome 3629 3EuroDYNA takes lid off the genome 3629 41 in 10 adults has a non earlobe piercing 21798 11 in 10 adults has a non earlobe piercing 21798 2New insight into RA patient priorities and motivators for clinical trial involvement 21796 1New insight into RA patient priorities and motivators for clinical trial involvement 21796 2New insight into RA patient priorities and motivators for clinical trial involvement 21796 3New STAY ON TRACK for Better Prostate Health Program Launches Fathers Day Weekend at NASCAR Race 21794 1New STAY ON TRACK for Better Prostate Health Program Launches Fathers Day Weekend at NASCAR Race 21794 2New STAY ON TRACK for Better Prostate Health Program Launches Fathers Day Weekend at NASCAR Race 21794 3New STAY ON TRACK for Better Prostate Health Program Launches Fathers Day Weekend at NASCAR Race 21794 4
...ALEM--(BUSINESS WIRE)--Mar 7, 2007 - BioLineRx Ltd...ompany, reported,today pre-clinical data from tria...ive in preventing deterioration of the myocardium,...ng left ventricle,dilatation and eventual heart fa... Director of the Neufeld Cardiac Research,Institut...
...t-Ever Placebo-controlled Study in Inoperable Chro...y Endpoint of,Reduction in Pulmonary Vascular Resi...ificant Effect on Dyspnoea Score and,Biological Di..., 2007 -Actelion Ltd (SWX:,ATLN) announced today t...controlled, multicenter study BENEFiT (Bosentan Ef...
Other Medicine Technology:BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 2BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 3Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 2Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 3Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 4Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 5Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 6
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
...'s National Eye Institute is seeking to raise glau... higher risk for the disease than others, the Cas...ans over age 60, blacks over age 40 and people wit...ace a higher risk for the disease. Five percent of...
...an article published in International Political So...ical pathologization of the Guantanamo detainees ,...etainment accredit the attempted suicides to the i...s the high prevalence of suicide attempts at the G...
... research to be published in BJOG: An Internationa...nk between the development of placenta praevia an...ncies of women who previously had a caesarean sect...as the implantation of the placenta over or near t...
...eaved families of firefighters who lost their live...eave a sigh of relief at last. Ontarios new labor ...cause of death in order to qualify for compensatio...hanges of regulations will identify eight types of...
Other Medicine News:Health News:Study Examines the Pathologization of Guantanamo Suicides 2Health News:Placental Problems in Women Linked With Caesarean Section 2Health News:Ontario Grants Fast-Track Compensation Rights for Work-Related Illnesses 2Health News:Ontario Grants Fast-Track Compensation Rights for Work-Related Illnesses 3
Adjustable tilt angle 0 to 20 Adjustable speed of 3-25 RPM Load capacity: 2.7 kg (6 lbs.) Ambient temperature range 4C to 65C Low voltage power is supplied by wall mount transformer
...al growth system, combines orbital shaking, oxygen...r bacterial growth. It is designed for easy integr...Extractor. The uniquely engineered HT-MegaGrowTM h...akers. Plate-holding cassettes allow for high plat...
Inquire
Inquire
Medicine Products: